Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
22
6
2021
medline:
12
10
2021
entrez:
21
6
2021
Statut:
ppublish
Résumé
Several studies have described the clinical features of COVID-19 in solid-organ transplant recipients. However, many have been retrospective or limited to more severe cases (hospitalized) and have not routinely included serial virological sampling (especially in outpatients) and immunologic assessment. Transplant patients diagnosed with COVID-19 based on a respiratory sample PCR were prospectively followed up to 90 d. Patients provided consent for convalescent serum samples and serial nasopharyngeal swabs for SARS-CoV-2 antibody (antinucleoprotein and anti-RBD) and viral load, respectively. In the 161 SOT recipients diagnosed with COVID-19, the spectrum of disease ranged from asymptomatic infection (4.3%) to hospitalization (60.6%), supplemental oxygen requirement (43.1%), mechanical ventilation (22.7%), and death (15.6%). Increasing age (OR, 1.031; 95% CI, 1.001-1.062; P = 0.046) and ≥2 comorbid conditions (OR, 3.690; 95% CI, 1.418-9.615; P = 0.007) were associated with the need for supplemental oxygen. Allograft rejection was uncommon (3.7%) despite immunosuppression modification. Antibody response at ≥14 d postsymptoms onset was present in 90% (anti-RBD) and 76.7% (anti-NP) with waning of anti-NP titers and stability of anti-RBD over time. Median duration of nasopharyngeal positivity was 10.0 d (IQR, 5.5-18.0) and shedding beyond 30 d was observed in 6.7% of patients. The development of antibody did not have an impact on viral shedding. This study demonstrates the spectrum of COVID-19 illness in transplant patients. Risk factors for severe disease are identified. The majority form antibody by 2 wk with differential stability over time. Prolonged viral shedding was observed in a minority of patients. Reduction of immunosuppression was a safe strategy.
Sections du résumé
BACKGROUND
Several studies have described the clinical features of COVID-19 in solid-organ transplant recipients. However, many have been retrospective or limited to more severe cases (hospitalized) and have not routinely included serial virological sampling (especially in outpatients) and immunologic assessment.
METHODS
Transplant patients diagnosed with COVID-19 based on a respiratory sample PCR were prospectively followed up to 90 d. Patients provided consent for convalescent serum samples and serial nasopharyngeal swabs for SARS-CoV-2 antibody (antinucleoprotein and anti-RBD) and viral load, respectively.
RESULTS
In the 161 SOT recipients diagnosed with COVID-19, the spectrum of disease ranged from asymptomatic infection (4.3%) to hospitalization (60.6%), supplemental oxygen requirement (43.1%), mechanical ventilation (22.7%), and death (15.6%). Increasing age (OR, 1.031; 95% CI, 1.001-1.062; P = 0.046) and ≥2 comorbid conditions (OR, 3.690; 95% CI, 1.418-9.615; P = 0.007) were associated with the need for supplemental oxygen. Allograft rejection was uncommon (3.7%) despite immunosuppression modification. Antibody response at ≥14 d postsymptoms onset was present in 90% (anti-RBD) and 76.7% (anti-NP) with waning of anti-NP titers and stability of anti-RBD over time. Median duration of nasopharyngeal positivity was 10.0 d (IQR, 5.5-18.0) and shedding beyond 30 d was observed in 6.7% of patients. The development of antibody did not have an impact on viral shedding.
CONCLUSIONS
This study demonstrates the spectrum of COVID-19 illness in transplant patients. Risk factors for severe disease are identified. The majority form antibody by 2 wk with differential stability over time. Prolonged viral shedding was observed in a minority of patients. Reduction of immunosuppression was a safe strategy.
Identifiants
pubmed: 34149003
doi: 10.1097/TP.0000000000003860
pii: 00007890-202110000-00014
pmc: PMC8487707
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2175-2183Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.
Kates OS, Haydel BM, Florman SS, et al. Coronavirus disease 2019 in solid organ transplant: a multicenter cohort study. Clin Infect Dis. [Epub ahead of print. August 7, 2020]. doi:10.1093/cid/ciaa1097
doi: 10.1093/cid/ciaa1097
Søfteland JM, Friman G, von Zur-Mühlen B, et al. COVID-19 in solid organ transplant recipients: a national cohort study from Sweden. Am J Transplant. 2021;21:2762–2773.
Roberts MB, Izzy S, Tahir Z, et al. COVID-19 in solid organ transplant recipients: dynamics of disease progression and inflammatory markers in ICU and non-ICU admitted patients. Transpl Infect Dis. 2020;22:e13407.
Chaudhry ZS, Williams JD, Vahia A, et al. Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: a cohort study. Am J Transplant. 2020;20:3051–3060.
Sharma P, Chen V, Fung CM, et al. COVID-19 outcomes among solid organ transplant recipients: a case-control study. Transplantation. 2021;105:128–137.
Yi SG, Rogers AW, Saharia A, et al. Early experience with COVID-19 and solid organ transplantation at a US high-volume transplant center. Transplantation. 2020;104:2208–2214.
Felldin M, Søfteland JM, Magnusson J, et al. Initial report from a Swedish high-volume transplant center after the first wave of the COVID-19 pandemic. Transplantation. 2021;105:108–114.
Adamson CS. Antiviral agents: discovery to resistance. Viruses. 2020;12:E406.
Ali T, Al-Ali A, Fajji L, et al. Coronavirus disease-19: disease severity and outcomes of solid organ transplant recipients: different spectrums of disease in different populations? Tranplantation. 2021;105:121–127.
Ali Malekhosseini S, Nikoupour H, Gholami S, et al. A report of 85 cases of COVID-19 and abdominal transplantation from a single center: what are the associated factors with death among organ transplantation patients. Transplantation. 2021;105:90–99.
Molnar MZ, Bhalla A, Azhar A, et al.; STOP-COVID Investigators. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant. 2020;20:3061–3071.
Miarons M, Larrosa-García M, García-García S, et al.; Vall d’Hebron COVID-19 Working Group. COVID-19 in solid organ transplantation: a matched retrospective cohort study and evaluation of immunosuppression management. Transplantation. 2021;105:138–150.
Benotmane I, Gautier-Vargas G, Wendling MJ, et al. In-depth virological assessment of kidney transplant recipients with COVID-19. Am J Transplant. 2020;20:3162–3172.
Lumley SF, O’Donnell D, Stoesser NE, et al.; Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021;384:533–540.
Azzi Y, Parides M, Alani O, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics. Kidney Int. 2020;98:1559–1567.
Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020;8:e70.
Fajnzylber J, Regan J, Coxen K, et al.; Massachusetts Consortium for Pathogen Readiness. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.
Thieme CJ, Anft M, Paniskaki K, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med. 2020;1:100092.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197.
Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020;58:e00941–e00920.
Theel ES, Harring J, Hilgart H, et al. Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2. J Clin Microbiol. 2020;58:e01243–e01220.
Elecsys Anti-SARS-CoV-2 S. Package Insert 2020-09, V1.0; material numbers 09289267190 and 09289275190e. Elecsys; 2020.
World Health Organization. Diagnostic detection of Wuhan coronavirus 2019 by real-time RT-PCR. 2020. Available at https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2 . Accessed May 20, 2021.
Public Health Ontario. SARS-CoV-2 (COVID-19 virus) variant of concern (VoC) surveillance. 2021. Available at https://www.publichealthontario.ca/en/laboratory-services/test-information-index/covid-19-voc . Accessed April 20, 2021.
Kumar D, Humar A, Keshavjee S, et al. A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors. Am J Transplant. 2021;21:2623–2624.
Government of Canada. Coronavirus disease 2019 (COVID-19): epidemiology update. 2021. Available at https://www.canada.ca/content/dam/phac-aspc/documents/services/diseases-maladies/2019-novel-coronavirus-infection/COVID19-epi-update-eng-2020-04-02.pdf . Accessed April 20, 2021.
Hartzell S, Bin S, Benedetti C, et al. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Am J Transplant. 2020;20:3149–3161.
Boyarsky BJ, Ou MT, Werbel WA, et al. Early development and durability of SARS-CoV-2 antibodies among solid organ transplant recipients: a pilot study. Transplantation. 2021;105:e52–e53.
Burack D, Pereira MR, Tsapepas DS, et al. Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection. Am J Transplant. 2021;21:2254–2261.
McCulloch DJ, Kim AE, Wilcox NC, et al. Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for detection of SARS-CoV-2 infection. JAMA Netw Open. 2020;3:e2016382.
Voysey M, Clemens SAC, Madhi SA, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
Zhu L, Gong N, Liu B, et al. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol. 2020;77:748–754.
Italiano J, Bush R, Acharya R, et al. Persistent viral shedding despite seroconversion in a kidney transplant recipient with severe extrapulmonary COVID-19. BMJ Case Rep. 2020;13:e239612.
Roedl K, Heidenreich S, Pfefferle S, et al. Viral dynamics of SARS-CoV-2 in critically ill allogeneic hematopoietic stem cell transplant recipients and immunocompetent patients with COVID-19. Am J Respir Crit Care Med. 2021;203:242–245.
Gaston DC, Malinis M, Osborn R, et al. Clinical implications of SARS-CoV-2 cycle threshold values in solid organ transplant recipients. Am J Transplant. 2021;21:1304–1311.
Theodore DA, Greendyke WG, Miko B, et al. Cycle thresholds among solid organ transplant recipients testing positive for SARS-CoV-2. Transplantation. 2021;105:1445–1448.